Orgenesis Completes Sale of Masthercell Subsidiary; Receives Approximately $127 Million in Net Proceeds
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59% 5-year CAGR of Masthercell under Orgenesis’ leadership Reports rapid progress in roll-out of point-of-care (POCare) platform to capitalize on industry demand for patient cell …